Forge Therapeutics is a biotechnology company developing novel medicines by combining bio-inorganic with medicinal chemistry to target metalloproteins. Forge has developed a fundamentally new approach for the discovery of metalloprotein inhibitors by focusing first on the metal in the enzyme active site.


Distinct from traditional approaches for ‘hit’ discovery using high throughput screens, the FORGE approach starts with metal-ligand interactions to identify selective metal-binding pharmacophore fragments from our proprietary library.  Using bio-inorganic and medicinal chemistry principles, full-length inhibitors are developed using a novel fragment growth strategy incorporating computational and structural biology.


Shining a light on a problem from a different direction can reveal undiscovered solutions.  At FORGE, we are uniquely discovering compounds that have potential for first-in-class medicines.  As an example of this differentiation, our LpxC inhibitor is the first ever non-hydroxamate to demonstrate in vivo efficacy.  Additionally, we are discovering new chemical scaffolds for our oncology programs, FG-KDM and FG-IDO, which overcome existing chemical limitations in their respective fields.



Forge was founded by leading bio-inorganic scientists and industry experts with the vision of creating a significant biotechnology company that couples pioneering metalloprotein technology with rigorous research to create life-saving medicines in areas of high unmet needs.


Zachary Zimmerman, Ph.D.

Chief Executive Officer

David Puerta, Ph.D.

Chief Operating Officer and Vice President of Discovery

Min Teng, Ph.D.

Senior Principal Scientist, Medicinal Chemistry

Konstantin Taganov, Ph.D.

Principal Scientist, Biology

Baskar Nammalwar, Ph.D.

Research Scientist, Synthetic Chemistry

Xiaoming Li, Ph.D.

Principal Scientist, Medicinal Chemistry


Seth Cohen, Ph.D.

Professor of Chemistry, University of California San Diego Click here to learn more

David Puerta, Ph.D.

Chief Operating Officer and Vice President of Discovery Click here to learn more

Zachary Zimmerman, Ph.D.

Chief Executive Officer Click here to learn more


Bob Baltera

CEO of Hawkeye Therapeutics and former CEO of Amira Pharmaceuticals

Tom Coll

Partner at Cooley LLC

Neil Gibson, Ph.D.

former CSO of Regulus Therapeutics, Pfizer Oncology, and OSI

John Schmid

former CFO of Auspex and Trius

Steve Worland, Ph.D.

CEO of eFFECTOR and former CEO of Anadys


Karen Joy Shaw, Ph.D.

former Trius, Johnson & Johnson, and Schering Plough; led microbiology strategy for Tedizolid

Michael Barbachyn, Ph.D.

former Director Antibacterial Chemistry at Pfizer & AstraZeneca; inventor of ZYVOX

Lynn Silver, Ph.D.

former Senior Investigator at Merck;
discovered LpxC and developed INVANZ

Robert Bonomo, M.D.

Case Western Reserve University,
Professor of Medicine and Microbiology Chief

Brad Spellberg, M.D.

Chief Medical Officer, Los Angeles County & University of Southern California Medical Center

Andrew Tomaras, Ph.D.

former LpxC program leader at Pfizer

Partners and Investors

Partnering: Forge Therapeutics is keenly interested in partnering with companies on the discovery and development of novel inhibitors targeting metalloproteins.  Our strategy is to utilize business development to add programs and build our pipeline.  We incorporate a balanced approach of internal and external programs to create a leading portfolio of first-in-class and best-in-class medicines for high unmet medical needs.

Janssen Logo
Discovering metalloenzyme inhibitors
for certain disease targets.

Investors: Forge Therapeutics raised a seed round in 2015 from friends & family, financial professionals, and angel investors.


Testing Forge antibiotics in infection models.

Testing Forge compounds
in cancer models.

Collaboration to validate ‘drugability’
of Jumonji KDMs


Strategic ‘superbug’ alliance to advance novel class of antibiotics

Contact Us

Forge Therapeutics, Inc.

3210 Merryfield Row

San Diego, CA 92121